The summary of clinical characteristics of lenvatinib induced pneumothorax in the literature with our cases
Age/sex | Cancer type | Surgery | Lung metastasis | Other distant metastases | Cavitations of metastatic lung nodules after lenvatinib | Pneumothorax | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptom | Time from lenvatinib initiation | Bilaterality | Lenvatinib dose at the moment of pulmonary event | Treatment | Lenvatinib therapy | Disease response to lenvatinib | |||||||
Kazzaz et al.6) | 73/M | ATC | TT | + | Mediastinal lymph nodes | + | Mild dyspnea | 2 months | Bilateral | NA | Chest tubing and chemical pleurodesis | Temporary cessation and restart with lower dose | Progression during lenvatinib withhold. |
Yamazaki et al.7) | 63/M | ATC | None | + | NA | + | None | 34 days | Unilateral | 20 mg |
Chest tubing | Maintenance | SD |
Lee et al.27) | 77/M | ATC | None | + | None | Dyspnea | 50 days | Bilateral | 24 mg |
Chest tubing and wedge resection | Temporary cessation and restart with lower dose (20 mg) | SD → patient died before 1 month after lenvatinib restarting | |
Kawanishi et al.30) | 71/M | HCC | None | + | None | + | Dyspnea, back pain | 2 months | Unilateral | 12 mg |
Thoracoscopic wedge resection and chest tubing | Cessation | PD → patients died ten days after discharge |
Our case 1 (case 2) | 49/F | ATC | None | + | Bone, liver | + | None | 353 days | Unilateral | 14 mg |
Supportive care | Temporary cessation and restart at the same dose | PD |
Our case 2 (case 3) | 80/F | PDTC | TT | + | Bone | + | None | 292 days | Unilateral | 10 mg |
Supportive care | Maintenance | SD |
ATC: anaplastic thyroid cancer, HCC: hepatocellular carcinoma, NA: not applicable, PD: progressive disease, PDTC: poorly differentiated thyroid cancer, SD: stable disease, TT: total thyroidectomy
aThe lenvatinib dose at the moment of pulmonary event is the same as the median daily dose before the event.